Subscribe To
Zyversa therapeutics’ ceo, stephen c. glover, to participate in a.g.p.’s virtual healthcare conference
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux Med...
May 11, 2023, 1:07 pm
Applied therapeutics reports first quarter 2023 financial results
Demonstrated Long-term Clinical Benefit of Govorestat in ACTION-Galactosemia Kids Trial Strengthened Balance Sheet with $30 Million Private Placement ...
May 11, 2023, 11:00 am
Geron presentations at upcoming eha annual meeting to report updated durability, disease modification and favorable patient reported outcomes (pro) in imetelstat-treated lower risk mds patients in ime
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that five abs...
May 11, 2023, 10:02 am
Questex’s international beauty show and international esthetics, cosmetics and spa conference’s co-located las vegas mega-floor to bring premier exhibitors
Longer Expo Floor Hours Create More Opportunity for Attendees to “Say Yes to You” NEW YORK, May 10, 2023 (GLOBE NEWSWIRE) — Questex’s Internat...
May 10, 2023, 5:00 pm
Cinemark to participate in j.p. morgan global tmt investor conference
PLANO, Texas--(BUSINESS WIRE)--Cinemark Holdings, Inc. (NYSE: CNK), one of the largest motion picture exhibito...
May 10, 2023, 5:00 pm
Cardiometabolic disease market size worth usd 868.45 billion by 2032 at 24% cagr – report by market research future (mrfr)
Cardiometabolic Disease Market Trends and Insights By Treatment (Angiotensin-converting Enzyme (ACE) Inhibito<...
May 10, 2023, 2:45 pm
New results from phase 2 trial confirm benefit of trilaciclib in reducing adverse events related to an antibody drug conjugate (adc)
– On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with Sacituzumab Govitecan-Hziy by Over 50% Including Neutrope...
May 10, 2023, 11:31 am
Inhibikase therapeutics to report first quarter financial results on may 15, 2023
BOSTON and ATLANTA , May 8, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceuti...
May 8, 2023, 8:05 am
Deluxe corporation (dlx) q1 2023 earnings call transcript
Deluxe Corporation (NYSE:DLX ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Tom Mora...
May 6, 2023, 5:45 pm
Biopharmaceutical excipients market size worth usd 2.24 billion by 2030 at 5.70% cagr – report by market research future (mrfr)
Biopharmaceutical Excipients Market Trends and Insights By Product {Solubilizers & Surfactants/Emulsifiers (Triglycerides, Esters), Polyols (Mannitol,...
May 5, 2023, 1:45 pm
Fmas:23 session spotlight – crypto in africa: crypto continent in the making?
In less than one week, the highly anticipated Finance Magnates Africa Summit (FMAS:23) will be underway in sunny South Africa. As the biggest and most...
May 4, 2023, 7:58 pm
Fmas:23 session spotlight – fintech in africa: opportunities in financial services
The Finance Magnates Africa Summit (FMAS:23) will be kicking off in only a few short days in Johannesburg, South Africa. The event of the year in Afri...
May 4, 2023, 7:48 pm
Prophase labs’ linebacker-1 cancer therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to-treat cancers, including l
Garden City, NY, May 03, 2023 (GLOBE NEWSWIRE) — ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagno...
May 3, 2023, 12:30 pm
Verona pharma to present expanded analyses of positive phase 3 enhance studies in copd in multiple presentations at ats 2023
12 Abstracts and one Symposium further support potential of ensifentrine, a first-in-class, selective, dual inhi...
May 2, 2023, 2:00 am
Fmas:23 session spotlight – fintech security
The Finance Magnates Africa Summit (FMAS:23) will be officially under way in less than one week at the world-famous Sandton Convention Centre in Johan...
May 1, 2023, 10:07 am
Astria therapeutics to present star-0215 at the 13th c1-inhibitor deficiency and angioedema workshop
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary ang...
April 28, 2023, 8:00 am
Kalvista pharmaceuticals to present data at the 13th c1-inhibitor deficiency & angioedema workshop
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical compa...
April 27, 2023, 6:30 am
Erasca announces two poster presentations at the 2023 asco annual meeting
Posters will feature preliminary Phase 1b combination data for potential best-in-class ERK1/2 inhibitor...
April 26, 2023, 9:00 pm
Arbutus biopharma clinical hold slows hepatitis b momentum: broker
Analysts at Baird Equity Research have awarded Arbutus Biopharma a ‘Neutral' rating after the early-stage biopharmaceutical company announced that ...
April 26, 2023, 2:44 pm
Arbutus announces fda clinical hold on ind application for ab-101, an oral pd-l1 inhibitor
WARMINSTER, Pa., April 25, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-sta...
April 25, 2023, 11:30 am